Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Second chance: drug combo retested for leukemia relapse

NCT ID NCT04895436

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a second course of venetoclax plus obinutuzumab can control chronic lymphocytic leukemia (CLL) when it comes back after initial treatment. About 75 adults whose CLL returned after prior successful therapy will receive the drug combination for up to 24 cycles. Researchers will monitor tumor shrinkage, side effects, and overall response to see if retreatment is effective and safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented diagnosis of chronic lymphocytic leukemia (CLL) that requires treatment for CLL according to International Workshop for Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria. * Previously completed venetoclax + anti-CD20 antibody +/- X regimen as a fixed duration first-line (1L) therapy and achieved documented response, defined as complete remission, complete remission with incomplete marrow recovery, partial remission, or nodular partial remission. * More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last dose of venetoclax and disease progression after completion of 1L treatment. Exclusion Criteria: \- Received intervening treatment for CLL after completing previous treatment with a venetoclax + anti-CD20 antibody +/- X regimen.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia (CLL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia (CLL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    50 sites in 11 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 229504

    RECRUITING

    Turin, Piedmont, 10126, Italy

  • Azienda Ospedaliera Santa Maria Terni /ID# 229442

    RECRUITING

    Terni, 05100, Italy

  • BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 230168

    RECRUITING

    Dresden, Saxony, 01307, Germany

  • Blackpool Victoria Hospital /ID# 267280

    RECRUITING

    Blackpool, Lancashire, FY3 8NR, United Kingdom

  • Bruederkrankenhaus St. Josef Paderborn /ID# 230177

    RECRUITING

    Paderborn, 33098, Germany

  • Charite Universitaetsmedizin Berlin Campus Virchow-Klinikum /ID# 248748

    RECRUITING

    Berlin, 13353, Germany

  • Dana-Farber Cancer Institute /ID# 230061

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Des Moines Oncology Research Association /ID# 232606

    COMPLETED

    Des Moines, Iowa, 50309-1423, United States

  • Duplicate_DIAKO Ev. Diakonie-Krankenhaus gemeinnuetzige GmbH /ID# 230238

    COMPLETED

    Bremen, 28239, Germany

  • Fundeni Clinical Institute /ID# 241614

    RECRUITING

    Bucharest, Bucharest, 022328, Romania

  • Hadassah /ID# 245059

    RECRUITING

    Jerusalem, Jerusalem, 91120, Israel

  • Hanusch Krankenhaus /ID# 230010

    RECRUITING

    Vienna, 1140, Austria

  • Hattiesburg Clinic /ID# 233443

    RECRUITING

    Hattiesburg, Mississippi, 39401, United States

  • Henry Ford Hospital /ID# 230268

    COMPLETED

    Detroit, Michigan, 48202, United States

  • Hospital Nove de Julho /ID# 243658

    RECRUITING

    São Paulo, São Paulo, 01409-001, Brazil

  • Hospital Universitario de la Princesa /ID# 229665

    RECRUITING

    Madrid, 28006, Spain

  • Hospital de Clinicas de Porto Alegre /ID# 243657

    COMPLETED

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Instituto de Ensino e Pesquisas Sao Lucas /ID# 243659

    RECRUITING

    São Paulo, 01236-030, Brazil

  • Klinik Ottakring /ID# 230019

    RECRUITING

    Vienna, State of Vienna, 1160, Austria

  • Klinikum Landshut AdöR der Stadt Landshut /ID# 242991

    RECRUITING

    Landshut, 84034, Germany

  • Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 267569

    RECRUITING

    Leoben, Styria, 8700, Austria

  • Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 230015

    COMPLETED

    Salzburg, 5020, Austria

  • Leeds Teaching Hospitals NHS Trust /ID# 250732

    RECRUITING

    Leeds, West Yorkshire, LS9 7TF, United Kingdom

  • MHAT Hristo Botev /ID# 229687

    RECRUITING

    Vratsa, 3000, Bulgaria

  • Medizinische Universitaet Wien /ID# 230013

    RECRUITING

    Vienna, State of Vienna, 1090, Austria

  • Moores Cancer Center at UC San Diego /ID# 230157

    RECRUITING

    La Jolla, California, 92093, United States

  • Muenchen Klinik Schwabing /ID# 230197

    COMPLETED

    Munich, Bavaria, 80804, Germany

  • Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 250733

    RECRUITING

    Norwich, Norfolk, NR4 7UY, United Kingdom

  • Northern Hospital Epping /ID# 229847

    RECRUITING

    Epping, Victoria, 3076, Australia

  • Novant Health Forsyth Medical Center /ID# 249533

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • Novant Health Presbyterian Medical Center /ID# 230201

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • OncoResearch Lerchenfeld GmbH /ID# 230191

    RECRUITING

    Hamburg, 22081, Germany

  • Onkologische Schwerpunktpraxis /ID# 245465

    RECRUITING

    Berlin, 10707, Germany

  • Ordensklinikum Linz GmbH Barmherzige Schwestern /ID# 249516

    RECRUITING

    Linz, Upper Austria, 4010, Austria

  • Pennsylvania Oncology Hematolo /ID# 249637

    RECRUITING

    Philadelphia, Pennsylvania, 19106, United States

  • Peter MacCallum Cancer Ctr /ID# 254634

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Rabin Medical Center. /ID# 243220

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Regional Cancer Care Associates /ID# 244620

    RECRUITING

    Hackensack, New Jersey, 07601-7015, United States

  • Royal Adelaide Hospital /ID# 229898

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • St. Lukes Hospital of Duluth /ID# 250021

    RECRUITING

    Duluth, Minnesota, 55805, United States

  • Stauferklinikum Schwaebisch Gmuend /ID# 230176

    RECRUITING

    Mutlangen, Baden-Wurttemberg, 73557, Germany

  • Summit Medical Group-Florham Park /ID# 244782

    COMPLETED

    Florham Park, New Jersey, 07932-1049, United States

  • Tel Aviv Sourasky Medical Center /ID# 243218

    RECRUITING

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Chaim Sheba Medical Center /ID# 243219

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The Ohio State University /ID# 230439

    RECRUITING

    Columbus, Ohio, 43210, United States

  • UMHAT Sveti Georgi EAD /ID# 272321

    RECRUITING

    Plovdiv, 4002, Bulgaria

  • Universitaetsklinikum Essen /ID# 230181

    RECRUITING

    Essen, 45147, Germany

  • Universitaetsklinikum Halle (Saale) /ID# 245350

    RECRUITING

    Halle, 06120, Germany

  • Universitaetsklinikum Koeln /ID# 230296

    RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 230186

    RECRUITING

    Kiel, Schleswig-Holstein, 24105, Germany

  • Universitaetsklinikum St. Poelten /ID# 243493

    RECRUITING

    Sankt Pölten, Lower Austria, 3100, Austria

  • Universitaetsklinikum Ulm /ID# 230164

    RECRUITING

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Universitaetsklinikum des Saarlandes /ID# 248747

    RECRUITING

    Homburg, Saarland, 66424, Germany

  • Universitaetsmedizin Rostock /ID# 230190

    RECRUITING

    Rostock, Mecklenburg-Vorpommern, 18057, Germany

  • University of North Carolina /ID# 233313

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • University of Wisconsin-Madiso /ID# 232612

    COMPLETED

    Madison, Wisconsin, 53705, United States

  • VK&K Studien GbR /ID# 230198

    RECRUITING

    Landshut, Bavaria, 84036, Germany

  • Winship Cancer Institute of Emory University /ID# 230643

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.